Dimitrios C Mastellos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5570576/publications.pdf

Version: 2024-02-01

72	7,201	87723 38	88477 70
papers	citations	h-index	g-index

79	79	79	8607
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 2022, 235, 108785.	1.4	30
2	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	4.0	31
3	C3-targeted host-modulation approaches to oral inflammatory conditions. Seminars in Immunology, 2022, 59, 101608.	2.7	9
4	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde. Seminars in Immunology, 2022, 60, 101640.	2.7	2
5	Emerging opportunities for C3 inhibition in the eye. Seminars in Immunology, 2022, 59, 101633.	2.7	5
6	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Progress in Retinal and Eye Research, 2021, 83, 100936.	7.3	37
7	Response to â€œComment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19â€. Clinical Immunology, 2021, 222, 108617.	1.4	0
8	Bactericidal Action of Smooth and Plasma Microâ€Nanotextured Polymeric Surfaces with Varying Wettability, Enhanced by Incorporation of a Biocidal Agent. Macromolecular Materials and Engineering, 2021, 306, 2000694.	1.7	20
9	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
10	C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends in Immunology, 2021, 42, 856-864.	2.9	27
11	Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology, The, 2021, 3, e95.	2.2	6
12	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	47
13	Enhanced antibacterial activity of ZnO-PMMA nanocomposites by selective plasma etching in atmospheric pressure. Micro and Nano Engineering, 2021, 13, 100098.	1.4	17
14	Isothermal Recombinase Polymerase Amplification (RPA) of E. coli gDNA in Commercially Fabricated PCB-Based Microfluidic Platforms. Micromachines, 2021, 12, 1387.	1.4	11
15	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 2020, 220, 108598.	1.4	191
16	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology, 2020, 215, 108450.	1.4	252
17	Complement as a target in COVID-19?. Nature Reviews Immunology, 2020, 20, 343-344.	10.6	426
18	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	1.4	16

#	Article	IF	Citations
19	Complement and tissue factorâ€“enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. Journal of Clinical Investigation, 2020, 130, 6151-6157.	3.9	580
20	Complement C3 as a Target of Host Modulation in Periodontitis. , 2020, , 13-29.		1
21	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
22	â€˜Stealthâ€™ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	7.0	7
23	New insights into the immune functions of complement. Nature Reviews Immunology, 2019, 19, 503-516.	10.6	281
24	Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Frontiers in Immunology, 2019, 10, 337.	2.2	69
25	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 2019, 10, 406.	2.2	60
26	A modular integrated lab-on-a-chip platform for fast and highly efficient sample preparation for foodborne pathogen screening. Sensors and Actuators B: Chemical, 2019, 288, 171-179.	4.0	34
27	Therapeutic targeting of the complement system. Nature Reviews Drug Discovery, 2019, , .	21.5	37
28	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. Clinical Immunology, 2019, 198, 102-105.	1.4	11
29	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 3029.	2.2	6
30	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
31	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
32	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell, 2018, 34, 531-533.	7.7	4
33	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
34	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
35	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
36	Novel mechanisms and functions of complement. Nature Immunology, 2017, 18, 1288-1298.	7.0	364

#	Article	IF	Citations
37	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
38	Complement component C3 â€“ The â€œSwiss Army Knifeâ€•of innate immunity and host defense. Immunological Reviews, 2016, 274, 33-58.	2.8	313
39	Complement therapeutics in inflammatory diseases: promising drug candidates for C3â€targeted intervention. Molecular Oral Microbiology, 2016, 31, 3-17.	1.3	36
40	3,4-Diaminobenzoic Acid Derivatives as Inhibitors of the Oxytocinase Subfamily of M1 Aminopeptidases with Immune-Regulating Properties. Journal of Medicinal Chemistry, 2015, 58, 1524-1543.	2.9	32
41	Compstatin: a C3â€targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 2015, 45, 423-440.	1.7	178
42	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
43	Attenuation of Staphylococcus aureusâ€“Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. Journal of Immunology, 2015, 195, 3946-3958.	0.4	9
44	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43
45	Complement emerges as a masterful regulator of CNS homeostasis, neural synaptic plasticity and cognitive function. Experimental Neurology, 2014, 261, 469-474.	2.0	30
46	Inducing and Characterizing Liver Regeneration in Mice: Reliable Models, Essential â€œReadoutsâ€•and Critical Perspectives. Current Protocols in Mouse Biology, 2013, 3, 141-170.	1.2	4
47	Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Seminars in Immunology, 2013, 25, 29-38.	2.7	72
48	cDNA cloning and phylogenetic analysis of the sixth complement component in rainbow trout. Molecular Immunology, 2006, 43, 1080-1087.	1.0	30
49	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
50	Cross-Disciplinary Research Stirs New Challenges into the Study of the Structure, Function and Systems Biology of Complement. Advances in Experimental Medicine and Biology, 2006, 586, 1-16.	0.8	4
51	Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development. Inflammation and Allergy: Drug Targets, 2005, 4, 125-127.	3.1	24
52	Novel biological networks modulated by complement. Clinical Immunology, 2005, 115, 225-235.	1.4	42
53	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. Journal of Immunology, 2004, 173, 2524-2529.	0.4	97
54	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. Journal of Immunology, 2004, 173, 747-754.	0.4	155

#	Article	IF	Citations
55	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Molecular Immunology, 2004, 40, 1213-1221.	1.0	57
56	From atoms to systems: a cross-disciplinary approach to complement-mediated functions*1. Molecular Immunology, 2004, 41, 153-164.	1.0	10
57	Complement: Structure, Functions, Evolution, and Viral Molecular Mimicry. Immunologic Research, 2003, 27, 367-386.	1.3	53
58	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâ˜†,â˜†â˜†. Clinical Immunology, 2003, 108, 263-273.	1.4	53
59	Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection. Journal of Immunology, 2003, 170, 788-794.	0.4	105
60	The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration. Journal of Experimental Medicine, 2003, 198, 913-923.	4.2	385
61	Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood, 2003, 101, 3784-3793.	0.6	217
62	Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal, 2002, 16, 1567-1574.	0.2	152
63	Herpes Simplex Virus Type 1 Evades the Effects of Antibody and Complement In Vivo. Journal of Virology, 2002, 76, 9232-9241.	1.5	91
64	Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood, 2002, 100, 4544-4549.	0.6	44
65	Complement: more than a â€˜guardâ€™ against invading pathogens?. Trends in Immunology, 2002, 23, 485-491.	2.9	144
66	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	141
67	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	103
68	Cloning and purification of the rainbow trout fifth component of complement (C5). Developmental and Comparative Immunology, 2001, 25, 419-430.	1.0	54
69	Phylogenetic aspects of the complement system. Developmental and Comparative Immunology, 2001, 25, 745-762.	1.0	118
70	A Novel Role of Complement: Mice Deficient in the Fifth Component of Complement (C5) Exhibit Impaired Liver Regeneration. Journal of Immunology, 2001, 166, 2479-2486.	0.4	220
71	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. Journal of Experimental Medicine, 1999, 190, 1637-1646.	4.2	108
72	Complement as a target in COVID-19?. , 0, .		1